Equibles does not estimate personal net worth.
Get an email with a short summary when Xenon Pharmaceuticals Inc. publishes a filing, an earnings call transcript or a press release.
Get XENE alertsThomas Kelly is recorded as CFO at Xenon Pharmaceuticals Inc. (XENE). The newest filing on record that lists Thomas Kelly as CFO at Xenon Pharmaceuticals Inc. (XENE) is dated April 22, 2026. The proxy statement of Xenon Pharmaceuticals Inc. reports total compensation of $7,238,664 for Thomas Kelly in fiscal 2025, including a base salary of $114,545. Thomas Kelly has spoken on 1 earnings call across 1 company, most recently for Xenon Pharmaceuticals Inc. on November 3, 2025. Xenon Pharmaceuticals Inc. is classified in the Biotechnology industry within the Healthcare sector. Other leadership on record at Xenon Pharmaceuticals Inc. includes Ian Mortimer (CEO, Chief Accounting Officer and Board Member), Simon Pimstone (Chairman), Thomas (Tucker) Kelly (CFO) and 7 others.
“I'm thrilled to join Xenon at such a pivotal time as the company progresses X-TOLE2 with the goal of delivering positive top line results early next year and planning for the anticipated launch for azetukalner in epilepsy and beyond.”
Start not stated–present
Last confirmed April 22, 2026
Biotechnology · Healthcare
CFO
Compensation components disclosed in company proxy statements. Amounts are nominal USD; total is the company-reported figure.
| Fiscal year | Company | Role | Salary | Total |
|---|---|---|---|---|
| 2025 | Xenon Pharmaceuticals Inc. (XENE) | Chief Financial Officer | $114,545 | $7,238,664 |
